Lines of Research:

  • Preclinical unit to advance the treatment of Acute Myeloblastic Leukaemia.
    • (Person in charge: Juan Manuel Alonso Domínguez MD, PhD.)
    • Prognostic markers and drug response predictors:
      • FLT3 ITD Mutation Length
      • CD33 Polymorphism as a Predictor of Response to GO
    • Epidemiology:
      • Study of the spatiotemporal appearance of AML
    • Leukaemic Stem Cells:
      • Study of Progenitor Quiescence and Differentiation Level
      • Expression as a Prognostic Marker and Possible Therapeutic Target in AML
    • Comparison of BCRABL/ABL1 measurement between qPCR and ddPCR
  • Preclinical unit for tissue engineering applied to haematopoietic and/or leukaemic niche. Microenvironment and drug response.
  • (Person in charge: Juana Serrano Lopez, PhD)
    • Tissue engineering for the simulation of the leukaemic niche in myeloid and lymphoid neoplasms by 3D printing. Drug response. Acronym: 3D-TELNICHE (Tissue Engineering to simulate a leukaemic niche by 3D printing).
    • Study of the microenvironment of the leukaemic niche in a 3D model generated by 3D printing tissue engineering.

  • Coagulopathies preclinical translational unit.
    • (In charge: Diego Velasco Rodríguez MD, PhD, Aránzazu García Raso, PhD and Rosa Vidal MD.)
    • Determination and impact of thrombin generation in patients on lupus anticoagulant.
    • Analysis of thrombotic phenotype of patients with the C46T polymorphism of the F12 gene.
    • Study of thrombin generation in patients with Multiple Myeloma pre-treatment, at one month after treatment, at 4 months, and in the event of relapse.
  • Preclinical translational unit for the genetic characterisation of myeloid neoplasms.
    • (Person in charge: Rocío Salgado Sánchez, PhD.)
    • Genetic characterisation by massive sequencing techniques for patients with MDS and CMML.
    • Association between mutational profiles and clinical-biological characteristics.
    • Analysis of clonal evolution mechanisms: genetic and phenotypic changes
  • Preclinical unit for immune effector cells applied to haematological malignancies. Development of new technologies.
    • (Person in charge: Juana Serrano López, PhD)
    • Lines of work:
    • Development of an anti-CD19 academic CART for the treatment of acute lymphoblastic leukaemia in adult and lymphoma patients.
    • Development of new virus-free technologies applied to the generation of CART effector immune cells.
    • Development of nanodevices that help reactivate the anti-tumour response in diffuse large B-cell lymphoma.
    • Development of gene therapy treatments for diseases such as pyruvate kinase deficiency (PKD), leukocyte adhesion deficiency (LAD), Fanconi Anaemia (FA).

Preclinical translational research

The FJD's Health Research Institute (IIS-FJD) has the infrastructure required for preclinical implementation of the cell therapy programme with CART cells. The IIS-FJD has several central services that support research, including:

  1. Biobank with collections of human samples obtained by clinical and research groups.
  2. Genomics Unit and Proteomics Laboratory.
  3. Epidemiology and Statistical and Bioinformatics Analysis Unit.
  4. Animal facility (experimental surgery unit and large/small animal housing).
  5. Imaging unit radiology service.
  6. Cell biology unit: confocal microscopy and flow cytometry.
  7. Radioisotope laboratory.

It should be noted that our group is equipped with tissue culture and molecular biology laboratories with PEC equipment, gel electrophoresis systems, proteomics systems, -80°C freezers, class II sterile cabinets, CO2 incubators, centrifuges and ultracentrifuges, flow cytometer, sorter, shaker, incubators, liquid nitrogen tanks, HPLC, fluorimeter, fluorescence microscopes.

(See Service Report in the section Description of the speciality for details of publications)


Fundación Jiménez Díaz's Haematology Department has a long history of teaching, which continues to this day through a range of different areas:

  • Undergraduate.
  • Postgraduate.
  • Doctoral theses.
  • Lifelong Medical Education.
  • Lifelong and Resident training (weekly clinical-teaching sessions).